Selling an Addiction Treatment Center in 2026: Multiples, Named Buyers, and the Operator Playbook

If you operate an addiction treatment center in 2026 — whether that is a small outpatient clinic, a multi-site IOP/PHP program, a residential treatment facility, or an MAT/opioid-treatment platform — the M&A market is highly active and capital-deep. Acadia Healthcare is the public behemoth, Universal Health Services operates diversified behavioral health, and PE sponsors (Webster Equity Partners, Linden Capital, Bain Capital, plus healthcare-focused funds) have backed multiple national platforms (BayMark, Pinnacle Treatment Centers, Discovery Behavioral Health, Behavioral Health Group). The buyer pool is real and writes platform-multiple checks for the right assets.

What the asset is worth depends on three things: (1) the payer mix and named in-network commercial contract status, (2) the level-of-care continuum (residential + PHP + IOP + outpatient + MAT integrated continuum is the premium model), and (3) the regulatory and clinical-quality infrastructure — Joint Commission or CARF accreditation, state licensing, medical-director compliance, and modern EMR (Kipu Health is the operator standard). This guide covers real multiples by profile, the named buyers transacting, and the operator-level diligence buyers will run.

If you operate an outpatient mental-health practice (psychiatry, psychology, therapy) without addiction treatment as the primary service line, our separate guide at how to sell a behavioral health practice is a better starting point.

Named addiction treatment M&A transactions (2022-2025)

The transactions below are public or widely-disclosed deals. They show a deeply capitalized buyer pool and an active market:

The named buyer landscape

The most important thing a seller needs to know is who is actually buying addiction treatment businesses right now, what they pay for, and what they will reject. The buyer pool falls into four buckets:

Public / strategic buyers

• Acadia Healthcare (NASDAQ: ACHC, ~$3B+ revenue) — the largest US public behavioral health operator. Pure-play behavioral and addiction treatment. Active acquirer.
• Universal Health Services (NYSE: UHS, $14B+ total revenue) — diversified hospital company with a $5B+ behavioral health segment. Selective behavioral acquirer.

PE-backed national platforms

• BayMark Health Services (Webster Equity Partners) — the largest US MAT (medication-assisted treatment) provider. Includes MedMark Treatment Centers (opioid treatment programs). Very active acquirer.
• Pinnacle Treatment Centers (Linden Capital + Webster Equity Partners) — continuum-of-care platform: residential, PHP, IOP, MAT. Active multi-state expansion.
• Discovery Behavioral Health (PE-backed) — residential treatment and eating-disorder programs.
• Behavioral Health Group (PE-backed) — pure-play opioid treatment programs (OTP) operator.
• Recovery Centers of America, Summit Behavioral Healthcare, Newport Healthcare, Caron Treatment Centers, Hazelden Betty Ford — multiple other national platforms, some PE-backed, some non-profit, all selective acquirers.

PE sponsors active in the space

• Webster Equity Partners — BayMark + Pinnacle (co-sponsor).
• Linden Capital — Pinnacle (co-sponsor) + multiple other healthcare investments.
• Bain Capital + Bain Double Impact — multiple behavioral health investments.
• Aterian Investment Partners, NMS Capital, Heritage Group, BlueMountain Capital — multiple PE funds active in behavioral and addiction treatment.

Subsegment-specific buyers

• MAT/OTP specific: BayMark, BHG, MedMark are the main consolidators.
• Residential: Acadia, Discovery Behavioral Health, Newport, Summit, plus boutique premium operators (Caron, Hazelden Betty Ford).
• Adolescent and eating disorders: Discovery, Newport, Eating Recovery Center (Trilantic North America).

What each buyer will pay for vs. what they reject

• Will pay premium for: named commercial in-network status with major payers (Anthem/Elevance, UHC, Aetna, Cigna, BCBS), Joint Commission or CARF accreditation with no findings, multi-state state-license footprint, integrated continuum of care (residential + PHP + IOP + outpatient + MAT), modern EMR (Kipu Health), documented utilization-review processes, clinical-outcomes data tracking (DAR/PHQ-9/GAD-7/CIWA), real medical-director and clinical leadership bench, documented insurance verification and prior-authorization workflows.
• Will compress or reject: Medicaid-heavy payer mix above ~50%, out-of-network billing model without commercial in-network contracts, accreditation gaps, open Joint Commission/CARF or state-licensing findings, single-payer concentration above 25%, owner-physician dependence, anti-kickback or patient-brokering exposure (huge in addiction historically), patient-protection-act compliance issues, undocumented utilization-review workflows, open OIG or state-licensing matters.

The operator-level KPI playbook buyers will diligence

Level-of-care mix and revenue composition

• Revenue mix by LOC: Residential %, PHP %, IOP %, outpatient %, MAT %. Integrated continuum-of-care is the premium model.
• Average length of stay (ALOS): Track by LOC. Residential ALOS 14-30+ days (varies by program), PHP 7-14 days, IOP weeks-to-months. Adherence and continuation rates are also tracked.
• Census/utilization: Average daily census, occupancy %, capacity utilization. Residential beds typically target 75-90% occupancy.
• Revenue per patient day (residential) / revenue per session (outpatient).

Payer mix and contracting

• Commercial percentage: 60%+ commercial is the platform benchmark for premium multiples. Below 40% commercial materially compresses.
• In-network status: Anthem/Elevance, UnitedHealthcare, Aetna, Cigna, BCBS-by-state — named in-network status is non-negotiable for the premium multiples.
• Single-payer concentration: No single payer over 25%.
• Out-of-network revenue: Document any OON billing methodology, allowable amounts, and patient-cost-share collection rates. OON-heavy models compress the multiple.
• Medicaid mix: <25% Medicaid is healthy; above 50% is a different buyer pool (state-Medicaid-focused operators).

Clinical operations and outcomes

• Clinical staffing model: Medical director, psychiatrist/addictionologist coverage, LCSW/LMFT/LPC counselors, nursing staffing ratios.
• Documented outcomes: Track PHQ-9, GAD-7, CIWA, COWS, ASAM-criteria adherence, and 30/60/90-day follow-up retention rates.
• Length-of-stay variance: Documented utilization-review processes and average days authorized per LOC.
• Discharge planning and aftercare: Documented discharge planning, alumni programs, recovery housing partnerships.

EMR and operating system

• EMR: Kipu Health is the operator-standard EMR for residential/IOP addiction treatment; other modern options include BestNotes, Sigmund, and AccuMedic.
• Insurance verification and prior-authorization: Documented workflow, average VOB turnaround, single-case-agreement (SCA) processes for OON.
• Utilization review (UR): Internal UR team, documented criteria adherence, average days authorized.
• Lab/toxicology: In-house lab or outsourced; document toxicology compliance carefully (anti-kickback historically).

Regulatory and licensing

• Accreditation: Joint Commission or CARF accredited, no findings, current surveys.
• State licensure: State-by-state licensure for every facility/location and every LOC.
• DEA + SAMHSA for MAT/OTP: OTP programs require DEA-X registration and SAMHSA CSAT registration (post-elimination of DEA-X form, current 8-hour education attestation in place).
• Medical-director compliance: Medical director credentialed and ASAM-certified where appropriate; documented hours and oversight.

Marketing and admissions

• Admissions volume: Inquiries, admissions, conversion rate, average daily admissions.
• Marketing source mix: Direct-to-consumer digital, professional referrals, insurance referrals, partial partnerships with EAPs/employee benefits.
• Patient-brokering compliance: Anti-kickback / EKRA compliance on referral relationships. Documented vendor management for digital marketing and call-center vendors.
• Census-management funnel: Documented financial-assistance, sliding-fee, and self-pay processes.

Dangers and traps in addiction treatment M&A

1. Patient-brokering and anti-kickback exposure

Addiction treatment has a documented history of patient-brokering enforcement actions (especially in Florida, California, Arizona). Any percentage-of-revenue marketer arrangements, sober-living kickbacks, lab-fee arrangements, or pay-per-admission relationships are EKRA / anti-kickback red flags that buyers will reprice or walk on. Counsel review and documented vendor compliance program before going to market.

2. Out-of-network billing model exposure

An OON-heavy revenue model has been repriced down meaningfully since the 2017-2019 enforcement and payer-pressure cycle. Premium multiples now require named commercial in-network contracts, and buyers model OON revenue as terminal-value-discounted.

3. Single-case agreement (SCA) revenue durability

If a meaningful share of revenue comes from one-off SCAs with payers, buyers question the durability and model the revenue down. Convert to in-network where possible; document SCA processes and approval rates carefully.

4. Toxicology lab fee arrangements

Definitive vs. presumptive UDS testing volumes, in-house lab vs. outsourced, lab-fee arrangements, and “POCT-plus-mass-spec” stacking have all been enforcement targets. Counsel review of toxicology compliance is non-negotiable.

5. Medical-director compliance

If medical director is fractional, multi-facility, or has compensation arrangements that look like marketing rather than clinical, expect repricing. Document medical-director hours, oversight, and credentials carefully.

6. State-licensing and Joint Commission/CARF findings

Open survey findings, conditional accreditation, or unresolved state-licensing matters are binary “walk” risks for most buyers. Resolve and document before going to market.

7. EMR and documentation hygiene

If you are on legacy systems or paper charts, expect a buyer-side integration discount and documentation-audit findings. Modern EMR (Kipu Health) is the operator standard.

8. Marketing-vendor relationships and PHI exposure

Call-center vendors, digital-marketing partners, and lead-generation relationships all create EKRA, anti-kickback, and HIPAA/PHI compliance exposure. Counsel review of every marketing relationship before going to market.

9. Adolescent / pediatric exposure

Adolescent residential treatment has additional regulatory, child-protective, and accreditation considerations. Document everything carefully and expect tighter buyer diligence.

10. Climate and accident/incident history

Resident overdoses, AMA discharges with adverse events, on-site safety incidents — track and document everything cleanly. Buyer-side risk diligence will scrutinize.

Our POV on addiction treatment M&A in 2026

The honest read on the market: addiction treatment is a deeply capitalized M&A space with two distinct halves — the heavily-PE/strategic-backed residential and continuum-of-care platforms, and the MAT/OTP consolidation (BayMark, BHG, MedMark).

• If you are a small single-site outpatient or IOP-only program, multiples are 3x-5x. Buyer pool is regional roll-ups and PE-backed continuum platforms doing geographic tuck-ins.
• If you are a regional outpatient + IOP + PHP program ($1-3M EBITDA), you are a tuck-in target for the PE-backed continuum platforms (Pinnacle, Discovery, Newport, Recovery Centers of America). Multiples 4x-7x.
• If you are a residential or MAT operator ($2-5M EBITDA), your buyer pool widens. MAT operators see BayMark, BHG, MedMark as the consolidators. Residential operators see Acadia, Discovery, Summit, Newport. Multiples 5x-8x.
• If you are a multi-site continuum-of-care platform ($5-15M EBITDA), you are most leveraged. The public strategics (Acadia, UHS) and the largest PE-backed platforms will pay 7x-10x.
• If you are a premium scale, multi-state platform ($15M+ EBITDA, named in-network, Joint Commission/CARF accredited, modern EMR, real clinical leadership), you are a strategic target. 9x-12x+ is achievable in a real competitive process.

The right time to prepare is 12-18 months before going to market — resolve any compliance matters, transition to in-network, modernize EMR, build the clinical leadership bench. Compliance is non-negotiable; the patient-brokering enforcement history of this sector makes it a binary “walk” issue for many buyers.

Preparing your addiction treatment center for sale: 12-18 months out

1. Run a compliance audit. Health-care counsel + behavioral-health compliance specialist should review patient-brokering / EKRA / anti-kickback exposure, toxicology lab arrangements, medical-director compliance, marketing vendor relationships, and PHI/HIPAA compliance. Resolve issues before going to market.
2. Transition to in-network where possible. Named commercial in-network contracts with the top 5 payers in your markets is the highest-leverage pre-sale work.
3. Get multi-year audited or reviewed financials. SCA, OON, and in-network revenue cleanly broken out. Document accounts-receivable aging carefully.
4. Confirm accreditation and state-licensing cleanliness. Joint Commission or CARF surveys clean and current. State-licensing current for every facility, every LOC, every state.
5. Modernize the EMR. Kipu Health is the operator standard. If you are on legacy systems or paper, plan the migration before going to market.
6. Document clinical outcomes. PHQ-9, GAD-7, CIWA, COWS, 30/60/90-day follow-up retention. Buyers want to see outcomes tracking.
7. Build the clinical leadership bench. Real medical director, clinical director, COO, and CFO who can stay through transition.
8. Document marketing-source mix and vendor compliance. Every digital marketing vendor, call-center vendor, and referral relationship documented as compliant.
9. Diversify payer concentration. No single payer above 25%.
10. Run a competitive process. Acadia, UHS, the PE-backed platforms (BayMark for MAT, Pinnacle/Discovery/Newport/Summit for continuum), the PE sponsors directly (Webster Equity, Linden, Bain, Aterian, NMS Capital), plus non-profit acquirers — a real auction with multiple buyers in the room is worth 1-3 turns of EBITDA over a single-bidder negotiation.

The five pillars of how CT Acquisitions works

Frequently asked questions

What is the typical multiple for an addiction treatment center in 2026?

Small single-site outpatient or IOP-only programs typically sell at 3x-5x EBITDA. Regional outpatient+IOP+PHP programs go 4x-7x. Small residential or MAT operators go 5x-8x. Multi-site continuum-of-care platforms go 7x-10x. Premium scale multi-state platforms with named commercial in-network contracts, Joint Commission/CARF accreditation, and modern operating infrastructure go 9x-12x+.

Who are the active buyers of addiction treatment businesses right now?

Public/strategic: Acadia Healthcare (NASDAQ: ACHC, ~$3B+ revenue), Universal Health Services (NYSE: UHS, $5B+ behavioral segment). PE-backed national platforms: BayMark Health Services (Webster Equity, largest US MAT provider), Pinnacle Treatment Centers (Linden Capital + Webster Equity), Discovery Behavioral Health (PE), Behavioral Health Group (PE, opioid treatment). PE sponsors directly: Webster Equity Partners, Linden Capital, Bain Capital, Aterian Investment Partners, NMS Capital, Heritage Group.

How is selling an addiction treatment center different from selling a behavioral health practice?

Addiction treatment centers (residential, IOP, PHP, MAT, OTP, SUD) have a distinct buyer pool and accreditation framework from outpatient mental health practices (psychiatry, psychology, therapy). The multiples, regulatory considerations (EKRA, patient-brokering, toxicology, DEA/SAMHSA for MAT), and consolidator buyer pool are different. See our separate guide at how-to-sell-a-behavioral-health-practice for outpatient mental health.

What hurts an addiction treatment center’s valuation most?

Patient-brokering / EKRA / anti-kickback exposure (historically the biggest enforcement risk in this sector), heavy Medicaid payer mix (above 50%), out-of-network billing model without in-network commercial contracts, accreditation gaps or open Joint Commission/CARF survey findings, open state-licensing matters, single-payer concentration above 25%, owner-physician dependence, undocumented utilization-review processes, and unresolved OIG or state matters.

What is the importance of Kipu Health and modern EMR in addiction treatment M&A?

Kipu Health is the operator-standard EMR for residential and IOP/PHP addiction treatment. It supports level-of-care documentation, ASAM criteria, utilization review workflows, clinical-outcomes tracking, and the regulatory documentation buyers expect. Operating on legacy systems or paper charts triggers buyer-side integration discount and documentation audit findings.

Do I have to pay a broker fee?

No. CT Strategic Partners runs a buyer-paid M&A advisory model. The seller pays nothing. The buyer pays the success fee at closing as part of their acquisition cost. This is structurally different from a traditional business-broker engagement.

How long does it take to sell an addiction treatment center?

Once you go to market with a buyer-paid advisor, a typical process runs 6-10 months from initial outreach to closing, with the longer end driven by regulatory and compliance diligence. Add 12-18 months of preparation work before going to market for the cleanest result.

When should I start preparing if I plan to sell in 2027 or 2028?

12-18 months before going to market is the right window. That gives time to clean up patient-brokering / EKRA / toxicology compliance, transition to in-network commercial contracts, modernize EMR (Kipu Health), document clinical outcomes, confirm accreditation and licensing cleanliness, and build the clinical leadership bench. Starting 3-6 months out leaves significant value on the table.

Related research

• How to sell a behavioral health practice (outpatient mental health)
• How to sell an ABA therapy business
• How to sell an infusion therapy business
• How to sell a home health agency
• How to sell an urgent care center
• How to sell a physical therapy practice
• How to sell a medical billing company
• Healthcare business valuation
• Which industries is PE buying most in 2026
• Business broker alternative

About the Author

Christoph Totter is the founder of CT Acquisitions, a buy-side partner headquartered in Sheridan, Wyoming. We work directly with 76+ buyers, search funders, family offices, lower middle-market PE, and strategic consolidators, including direct mandates with the largest home services consolidators that other intermediaries can’t access. The buyers pay us when a deal closes, not the seller. No retainer, no exclusivity, no contract until close. Connect on LinkedIn · Get in touch